Cycle on Aug 28, 2026

I am starting the research cycle by listing the open threads to see if there are any specific questions, investigations, or ongoing watches we need to address or monitor.

I will search for CARDIO-TTRansform and eplontersen to see if the full dataset has been presented at the ESC Congress 2026, which is happening around late August 2026.

I will fetch the ESC press release and the STAT News article to get details of the CARDIO-TTRansform trial results, as they were presented today, August 28, 2026. This is a crucial event that resolves one of our watches. Let's do a web_fetch of the ESC press release first.

I will search for the STAT News article about the AstraZeneca/Ionis CARDIO-TTRansform trial results to see the analysis of what this means for other drugs in the space, such as Alnylam's Amvuttra (vutrisiran) or BridgeBio's acoramidis. Let's do a web_search first.

Let's broaden the search query to look for STAT news articles about eplontersen and Alnylam from the last week.

I will fetch the STAT News article: "In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs" to get a deeper understanding of the market implications, particularly for Alnylam's vutrisiran (Amvuttra) and BridgeBio's acoramidis, and why the trial failed.

Now let's check for other major news. I will search for other health and science breakthroughs, drug approvals, or major trial readouts over the past week. First, let's search for "FDA approval" or "clinical trial" news from the past week. Let's do a search.

This is incredibly rich and exciting! Let's see what we have here: 1. **CARDIO-TTRansform trial failure (Wainua / eplontersen in ATTR-CM)**: This is a direct hit on a watch! - Thread/Watch: "CARDIO-TTRansform full dataset presentation at ESC Congress 2026" - Outcome: On August 28, 2026, the trial results were presented at the ESC Congress 2026 and published in NEJM. The trial did NOT meet its primary efficacy endpoint of reducing cardiovascular mortality and recurrent cardiovascular events up to 140 weeks, despite suppressing TTR. The failure is attributed to background stabilizer use (57% of patients were on stabilizers like tafamidis at baseline, and 24% initiated it during the trial), which masked any incremental benefit of eplontersen. - We must resolve this watch! Let's check the watch's ID: `019f490e-b47d-7dea-817e-56ffbad19c83`. 2. **FDA Approves Rasonque (daraxonrasib) for Metastatic Pancreatic Cancer**: - Date: August 26, 2026. - Details: Approved 6.5 months early (expedited/priority review, Breakthrough Therapy, Orphan Drug). Developed by Revolution Medicines. It is a first-of-its-kind "molecular glue" RAS inhibitor that blocks mutated proteins in >90% of pancreatic cancer cases. - Clinical trial: Phase 3 trial with 500 adults with previously treated metastatic pancreatic adenocarcinoma. Daraxonrasib nearly doubled overall survival (13.2 months vs 6.7 months for standard chemotherapy) and was published in NEJM earlier this year. - Cost: ~$39,800 for a one-month supply. - This is a major breakthrough in biology/medicine, fitting our brief perfectly! 3. **FDA Approves Gilead's Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg)**: - Date: August 27, 2026. - Details: Approved as a once-daily single tablet regimen (STR) for virologically suppressed adults with HIV, including those on complex regimens. It combines bictegravir (INSTI) and lenacapavir (first-in-class capsid inhibitor). It is the smallest once-daily STR. - Clinical trials: Phase 3 ARTISTRY-1 and ARTISTRY-2. - Note: We have a watch related to "Yeztugo (lenacapavir) 300-mg tablets as a potential once-weekly oral formulation for HIV PrEP" (PDUFA Feb 2, 2027) and "Gilead and Merck once-weekly oral HIV combination (islatravir/lenacapavir)". Bixlenvo is a different, daily oral combination of bictegravir and lenacapavir. 4. **HHS Plans New FDA Deputy Commissioner Roles**: - Date: August 25, 2026. - CNBC reports HHS plans new FDA deputy commissioner roles for technology and drugs. - In this article, it also mentions: - "And on Monday [August 24, 2026], the FDA granted a three-month review extension for Capricor Therapeutics' experimental Duchenne muscular dystrophy drug to consider additional data, which came after an advisory committee to the agency voted 9-3 against recommending approval of that product." - Let's check our watches: we have a watch for "FDA's new PDUFA target action date and regulatory decision on Capricor's amended BLA for deramiocel in DMD (upper limb function) once the amendment is formally accepted and a new action date is set by the FDA." (ID: `01a02157-258c-7181-a87b-06991ba47c2d`). Let's search for Capricor's extension to see if the new PDUFA date has been set! Let's do a search on Capricor's deramiocel extension.

This is incredibly useful! Let's review the events: 1. **CARDIO-TTRansform trial failure (Wainua / eplontersen in ATTR-CM)**: - On August 28, 2026, during the ESC Congress, the full Phase 3 CARDIO-TTRansform data was presented and published in NEJM. - The trial failed to meet its primary composite endpoint of cardiovascular mortality and recurrent cardiovascular events (rate ratio 0.89, p=0.277) over 140 weeks, despite successful suppression of circulating serum transthyretin (TTR). - The failure was driven by baseline stabilizer use (57% of patients on stabilizers like tafamidis at baseline, and 24% initiating them during the trial). No additional benefit was seen in patients on background stabilizers, though a nominal benefit was observed in patients not on stabilizers (eplontersen monotherapy). - This fires and resolves the watch: **CARDIO-TTRansform full dataset presentation at ESC Congress 2026** (ID: `019f490e-b47d-7dea-817e-56ffbad19c83`). Let's trigger a `record_event` on it, and then write a finding note for it. 2. **Capricor's deramiocel PDUFA date extension**: - On August 24, 2026, Capricor announced that the FDA extended the PDUFA target action date for its BLA for deramiocel in Duchenne muscular dystrophy (DMD) from August 22, 2026, to **November 22, 2026**. - The FDA classified the submission of additional Phase 3 HOPE-3 24-month open-label extension data and a refined indication focused on upper limb function as a "major amendment," triggering a three-month extension. - This fires and resolves the watch: **FDA's new PDUFA target action date and regulatory decision on Capricor's amended BLA for deramiocel in DMD** (ID: `01a02157-258c-7181-a87b-06991ba47c2d`). Let's record an event on it and then record a new watch for the new PDUFA date of November 22, 2026. 3. **FDA Approves Revolution Medicines' Rasonque (daraxonrasib)**: - On August 26, 2026, the FDA approved Rasonque (daraxonrasib) for adults with metastatic pancreatic cancer. This is a massive breakthrough. Let's write a finding note for this! 4. **FDA Approves Gilead's Bixlenvo (bictegravir/lenacapavir)**: - On August 27, 2026, the FDA approved Bixlenvo as a once-daily single tablet regimen for virologically suppressed adults with HIV on complex regimens. Let's write a finding note for this as well. Let's check if there are any other watches that might have fired. What about: - **Launch of NASA's Nancy Grace Roman Space Telescope**: - Watch description: "Monitor the launch of the Nancy Grace Roman Space Telescope aboard a SpaceX Falcon Heavy rocket from Kennedy Space Center, scheduled for August 30, 2026." (fire_date: August 30, 2026). - Let's search if there has been any update, delay, or prep news about this launch! It's scheduled for August 30, 2026, which is in 2 days. Let's see if there is any news about it.

Excellent. The Nancy Grace Roman Space Telescope is scheduled to launch on Sunday, August 30, 2026, at 7:26 a.m. EDT. This means the launch hasn't happened yet (it's currently August 28), but it is fully "GO" for launch on that date. Since it has not fired yet, we should keep the watch open and let the next cycle handle its firing once it has actually launched. Let's do a fast search to see if any other watches have fired or if there is any other major news we should cover. Let's check the watch list: - **EMA regulatory decision on Pasatru (garetosmab) in FOP** (Regeneron) - **Xspray Pharma NDA resubmission for Dasynoc** - **Scholar Rock's apitegromab BLA in SMA** (PDUFA date around Sept 30, 2026) - **argenx BLA submission for Vyvgart Hytrulo in autoimmune myositis** - **BMS Phase 3 EXCALIBER-RRMM data presentation** (Q4 2026) - **Regeneron Phase 3 OPTIMA 2 trial initiation** (Q4 2026) - **Launch of JAXA's MMX mission** (October 20, 2026) - **Merck/Moderna BLA submission for intismeran autogene in melanoma** - **PAHO decision on U.S. measles elimination status** (November 2026) - **Summit/Akeso Phase III HARMONi-3 trial results for ivonescimab** (H2 2026) - **BMS mezigdomide NDA decision** (May 2027) - **FDA Advisory Committee meeting on GRAIL's Galleri MCED test** (Sept 23, 2026) - **Definium Phase 3 Panorama trial readout of DT120 in GAD** (Sept 2026) - **ITM NDA resubmission for ITM-11 in GEP-NETs** - **Belite Bio tinlarebant NDA in Stargardt disease** (PDUFA Feb 2027) - **Tarsus/Alkeus Phase 3 NORTHSTAR trial results of gildeuretinol** - **Replimune Phase 3 IGNYTE-3 confirmatory trial results for Tudriqev** - **Saol's SL1009 (DCA) in PDCD** (PDUFA Dec 30, 2026) - **FDA final decision on compounding peptides 503A list addition** - **FDA response to CRL public disclosure citizen petition** (Oct 2026) - **New Zealand H5N1 transmission to poultry or wildlife sanctuaries** - **FDA final rule on CRL public disclosure (RIN 0910-AJ16)** - **Vera Therapeutics Phase 3 ORIGIN 3 eGFR confirmatory results in IgAN** (Q3 2026) - **Australia H5N1 transmission to poultry or local wildlife** - **Definium DT120 Phase 3 GAD and low-dose MDD trial readouts** (end of 2026) - **FDA finalization and launch of Expedited-IND Pilot Program** (Sept 2026) - **Sobi BLA resubmission for NASP in uncontrolled gout** - **Achieve Life Sciences NDA resubmission for cytisinicline** (Q4 2026) - **EMA re-examination outcome on Omeros's narsoplimab in TA-TMA** - **GondolaBio Phase 2b/3 PATHWAY trial initiation of PORT-77 in EPP** (Q3 2026) - **Merck regulatory filing for tulisokibart in ulcerative colitis** - **MoonLake BLA submission for sonelokimab in HS** (Sept 2026) - **FDA regulatory decision on Exelixis' zanzalintinib plus Tecentriq in late-line mCRC** (Dec 3, 2026) - **FDA traditional approval decision on Novartis's Vanrafia (atrasentan) in IgAN** (late 2026) - **Dianthus MoMeNtum Phase 2 top-line data in MMN** (Q4 2026) - **Dianthus CAPTIVATE Part B top-line guidance in CIDP** (end of 2026) - **uniQure BLA submission for AMT-130 in Huntington's disease** (Q3 2026) - **FDA regulatory decision on Gilead's once-weekly oral Yeztugo for HIV PrEP** (Feb 2, 2027) - **FDA regulatory decision on Zepzelca's second-line SCLC indication** - **USDA $750M sterile screwworm fly facility operational launch in Texas** - **Sanofi Tzield Phase 3 BETA-PRESERVE confirmatory trial in Stage 3 T1D** - **FDA regulatory filing and decision on Gilead/Merck once-weekly oral HIV combination** (islatravir/lenacapavir) - **FDA regulatory filing and decision on Takeda's zasocitinib in plaque psoriasis** - **FDA regulatory filing and decision on Eli Lilly's Foundayo in Type 2 diabetes** - **Sanofi riliprubart Phase 3 VITALIZE trial status and readout in CIDP** - **Dianthus Therapeutics claseprubart Phase 3 CAPTIVATE trial readout in CIDP** - **Eli Lilly SURPASS T1D-1 Phase 3 trial readout in Type 1 Diabetes** (Nov 2026) - **DIOSynVax AI-designed universal Sarbeco vaccine Phase II trial readout** - **Alterity Therapeutics ATH434 Phase 3 MSA trial initiation** - **Disc Medicine bitopertin Phase 3 APOLLO trial readout and FDA CRL decision** - **Pfizer berobenatide Phase 3 obesity trial readout** - **Phase 3 trial readout for VGA039 in von Willebrand disease** - **ISS Russian Zvezda module air leaks and repairs** - **FDA regulatory decision on giredestrant in HR+ early-stage breast cancer** (Nov 2026) - **FDA regulatory decision on bezuclastinib in GIST** (Nov 2026) - **Moderna Phase 3 mRNA-1018 bird flu vaccine trial readout** - **sBLA submission for Zynlonta plus rituximab in r/r DLBCL** (Q4 2026) - **NHS-Galleri trial cancer mortality data release** - **NMPA regulatory decision on IBI343 (world's first CLDN18.2 ADC)** - **Global Phase 3 trial readouts for ivonescimab (HARMONi studies)** - **Clinical trial initiation/readout for fast-tracked Bundibugyo Ebola vaccines** Let's check if there are any updates on some of the near-term ones, for example: - **Vera Therapeutics Phase 3 ORIGIN 3 eGFR confirmatory results in IgAN** (Q3 2026) - **uniQure BLA submission for AMT-130 in Huntington's disease** (Q3 2026) - **GondolaBio Phase 2b/3 PATHWAY trial initiation of PORT-77 in EPP** (Q3 2026) - **MoonLake BLA submission for sonelokimab in HS** (Sept 2026) - Let's do a quick search for Vera Therapeutics ORIGIN 3, uniQure AMT-130, GondolaBio PORT-77, and MoonLake sonelokimab.

Ah, that was a messy search query because of the word "Vera" which matched a TV series. Let's make it more specific and separate. Let's search for Vera Therapeutics ORIGIN 3 trial.

Okay, let's understand what happened with Vera Therapeutics: - The FDA approved Vera's **TRUTAKNA (atacicept)** under accelerated approval in July 2026 (announced around July 6-7, 2026). - In Vera's Q2 2026 business update (August 10, 2026), Vera stated that they "Aligned with the FDA on an earlier ORIGIN 3 final efficacy analysis to support potential full approval of TRUTAKNA in adults with IgAN." - Wait, let's check our watch description: "Monitor the readout of the confirmatory eGFR kidney function data from Vera Therapeutics' Phase 3 ORIGIN 3 trial of Trutakna (atacicept) in primary IgA nephropathy, expected in Q3 2026. This is required to support its accelerated approval." - Let's search specifically for the ORIGIN 3 confirmatory eGFR readout in Q3 2026 or any updates to its timing. Let's do a search.

Let's check if the final efficacy analysis of ORIGIN 3 has been released yet. According to the stocktitan.net text: "The final efficacy analysis from ORIGIN 3 is expected in the third quarter of 2026..." Wait, has it been released? Let's search for "Vera Therapeutics" "final efficacy analysis" "ORIGIN 3" "August" "2026". Let's do a search.

Ah, the search budget is spent. That is perfectly fine, we have plenty of high-quality, newly released information to write up our notes and update our watches. Let's carefully organize our findings. First, let's resolve the threads and watches that have fired: 1. **CARDIO-TTRansform full dataset presentation at ESC Congress 2026** (ID: `019f490e-b47d-7dea-817e-56ffbad19c83`): - This watch has fired! The full dataset was presented on August 28, 2026, at the ESC Congress and published in NEJM. Eplontersen missed its primary endpoint. - I will call `record_event` with `resolves: true` because it's a `one_shot` watch. 2. **FDA's new PDUFA target action date and regulatory decision on Capricor's amended BLA for deramiocel in DMD** (ID: `01a02157-258c-7181-a87b-06991ba47c2d`): - This watch has fired! On August 24, 2026, the FDA formally accepted the major amendment and established the new PDUFA date as November 22, 2026. - I will call `record_event` with `resolves: true` since the new date has been set. - I will register a *new* watch for the actual regulatory decision on November 22, 2026. Let's call `record_event` for both of these. Let's do it now.

Now let's record the event for Capricor's deramiocel watch.

Great. Let's record a new watch for the actual regulatory decision on Capricor's deramiocel BLA on its new PDUFA date: November 22, 2026. This will keep tracking it.

Now let's write our notes. We have 4 distinct themes/stories to write notes for. Let's make sure we write them under stable slugs, with concrete evidence, verbatim quotes, and links. Let's do them one by one. ### 1. CARDIO-TTRansform trial failure (Wainua / eplontersen in ATTR-CM) - Slug: `eplontersen-cardio-ttransform-trial-failure` - Title: `CARDIO-TTRansform: Eplontersen Fails to Meet Primary Endpoint in ATTR-CM due to Background Stabilizers` - Story: At the ESC Congress 2026 on August 28, the full Phase 3 results of CARDIO-TTRansform were presented and published in NEJM. The trial failed to meet the primary composite endpoint of cardiovascular mortality and recurrent cardiovascular events up to 140 weeks, despite substantial suppression of circulating TTR. Why did it fail? Background use of stabilizers (57% of patients on stabilizers like tafamidis at baseline, and an additional 24% initiating them during the trial) masked the benefit. No incremental benefit was observed in patients on stabilizers. However, eplontersen monotherapy (in patients not receiving a stabilizer) showed nominal statistical significance. - Sources: - https://www.escardio.org/news/press/press-releases/eplontersen-trial-did-not-meet-its-primary-endpoint-in-transthyretin-mediated-amyloid-cardiomyopathy/ - https://www.statnews.com/2026/08/28/astrazeneca-ionis-wainua-eplontersen-attr-cm-study-failure-bridgebio-alnylam/ Let's draft this note. I will write it now.

Excellent. Now let's write the second note. ### 2. FDA Approves Revolution Medicines' Rasonque (daraxonrasib) for Metastatic Pancreatic Cancer - Slug: `daraxonrasib-pancreatic-cancer-fda-approval` - Title: `FDA Approves Rasonque (daraxonrasib), Ushering in a New Era of Targeted Pancreatic Cancer Therapy` - Story: On August 26, 2026, the FDA approved Rasonque (daraxonrasib) for adults with metastatic pancreatic cancer. This is a massive milestone because it is a first-of-its-kind "molecular glue" RAS inhibitor that blocks mutated proteins in >90% of pancreatic cancer cases. In a Phase 3 trial of 500 patients, daraxonrasib nearly doubled overall survival to 13.2 months compared to 6.7 months for standard chemotherapy. The approval was granted 6.5 months ahead of schedule. The drug will cost approximately $39,800 for a one-month supply. - Sources: - https://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer - https://www.nbcchicago.com/news/health/fda-approves-pancreatic-cancer-drug-daraxonrasib/3980633/ - https://www.scientificamerican.com/article/u-s-approves-breakthrough-pancreatic-cancer-drug-heralding-a-new-era-for-an-intractable-disease/ Let's write this note. I will call `write_note` now.

Excellent. Now let's write the third note. ### 3. FDA Approves Gilead's Bixlenvo (bictegravir/lenacapavir) - Slug: `gilead-bixlenvo-hiv-fda-approval` - Title: `FDA Approves Gilead's Bixlenvo as the First Once-Daily STR for Complex HIV Regimens` - Story: On August 27, 2026, the FDA approved Gilead's Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg), which is the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. It is the first and only STR option for virologically suppressed people on complex regimens who are unable to take currently available STRs due to resistance or tolerability. It combines bictegravir (INSTI) with lenacapavir (capsid inhibitor). - Clinical trials: Phase 3 ARTISTRY-1 and ARTISTRY-2. ARTISTRY-1 enrolled an older patient population (median age 60) with a median treatment duration of 28 years and high historical resistance (67% with NRTI resistance). Switching to Bixlenvo maintained virologic suppression. - Sources: - https://investors.gilead.com/news/news-details/2026/U-S--FDA-Approves-Gileads-Bixlenvo-a-New-Once-Daily-Single-Tablet-Option-for-Virologically-Suppressed-Adults-With-HIV-Including-Those-on-Complex-Regimens/default.aspx Let's write this note. I will call `write_note` now.

Perfect. Now let's write the fourth note. ### 4. Capricor's deramiocel PDUFA date extension - Slug: `capricor-deramiocel-dmd-pdufa-extension` - Title: `FDA Grants Capricor a Three-Month PDUFA Extension for Deramiocel in Duchenne Muscular Dystrophy` - Story: On August 24, 2026, Capricor Therapeutics announced that the FDA extended the PDUFA target action date for its BLA for deramiocel (an investigational cell therapy for Duchenne muscular dystrophy) from August 22, 2026, to November 22, 2026. This extension occurred after Capricor submitted 24-month Phase 3 HOPE-3 open-label extension data and refined its proposed indication to focus specifically on upper limb function. The FDA classified this submission as a "major amendment," giving the agency three more months to review the data. - Sources: - https://www.capricor.com/investors/news-events/press-releases/detail/354/capricor-therapeutics-announces-extension-of-pdufa-target - https://www.biospace.com/fda/capricors-duchenne-therapy-has-new-life-after-fda-grants-3-month-extension - https://www.cgtlive.com/view/fda-extends-deramiocel-review-dmd Let's write this note. I will call `write_note` now.

Awesome. Let's check if there are any other threads we should resolve. Let's call `list_threads` again or just inspect the ones we saw: - `019f490e-b47d-7dea-817e-56ffbad19c83` is the CARDIO-TTRansform watch. I already called `record_event` on it with `resolves: true`. I should also call `resolve_thread` on it to officially close the thread. - `01a02157-258c-7181-a87b-06991ba47c2d` is the Capricor's deramiocel watch. I already called `record_event` on it with `resolves: true`. I should also call `resolve_thread` on it to officially close the thread. Let's do that now. I will resolve these two threads.

Now let's resolve the Capricor thread.

This is perfect. We have: - Resolved two outstanding watches/threads. - Added a new watch for the new deramiocel PDUFA date of Nov 22, 2026. - Written four detailed, highly relevant, and newly surfaced findings with stable slugs, verbatim quotes, and direct links to primary sources. - `eplontersen-cardio-ttransform-trial-failure` - `daraxonrasib-pancreatic-cancer-fda-approval` - `gilead-bixlenvo-hiv-fda-approval` - `capricor-deramiocel-dmd-pdufa-extension` Everything is fully documented, and no other threads or watches need to be addressed at this moment. I am ready to finish the cycle. Let's call `finish_cycle`.

I have successfully completed the research cycle. ### Summary of Actions Taken: 1. **Resolved Two Major Watches/Threads:** - **CARDIO-TTRansform Trial Failure (eplontersen in ATTR-CM):** Recorded the event and resolved the thread following the trial's full presentation at the ESC Congress 2026 on August 28, which showed eplontersen failed to meet its primary efficacy endpoint due to background stabilizer use. - **Capricor's Deramiocel PDUFA Extension:** Recorded the event and resolved the thread following the FDA's decision on August 24 to extend the target action date by three months to November 22, 2026, to review a major amendment. 2. **Registered a New Watch:** - **FDA Regulatory Decision on Capricor's Deramiocel BLA (November 22, 2026):** Created a new watch to monitor the FDA's final decision on this extended date. 3. **Wrote Four New Detailed Findings:** - `[[eplontersen-cardio-ttransform-trial-failure]]`: Explains the CARDIO-TTRansform Phase III trial failure, detailing how background stabilizer use masked eplontersen's therapeutic benefit. - `[[daraxonrasib-pancreatic-cancer-fda-approval]]`: Documents the landmark, early FDA approval of Revolution Medicines' Rasonque (daraxonrasib) for metastatic pancreatic cancer, heralding a new era of RAS-targeted therapy. - `[[gilead-bixlenvo-hiv-fda-approval]]`: Summarizes the FDA approval of Gilead's Bixlenvo (bictegravir/lenacapavir) as the first daily single-tablet regimen for adult patients on complex HIV regimens. - `[[capricor-deramiocel-dmd-pdufa-extension]]`: Details the FDA's three-month PDUFA extension for Capricor's deramiocel, along with its strategic pivot to narrow the indication to upper limb function using 24-month HOPE-3 OLE data.